<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <meta name="author" content="hbaolong@vip.qq.com" />
  <title>2804癌症传EN081-2026年01月27日-癌症传EN</title>
  <style>
    html {
      color: #1a1a1a;
      background-color: #fdfdfd;
    }
    body {
      margin: 0 auto;
      max-width: 36em;
      padding-left: 50px;
      padding-right: 50px;
      padding-top: 50px;
      padding-bottom: 50px;
      hyphens: auto;
      overflow-wrap: break-word;
      text-rendering: optimizeLegibility;
      font-kerning: normal;
    }
    @media (max-width: 600px) {
      body {
        font-size: 0.9em;
        padding: 12px;
      }
      h1 {
        font-size: 1.8em;
      }
    }
    @media print {
      html {
        background-color: white;
      }
      body {
        background-color: transparent;
        color: black;
        font-size: 12pt;
      }
      p, h2, h3 {
        orphans: 3;
        widows: 3;
      }
      h2, h3, h4 {
        page-break-after: avoid;
      }
    }
    p {
      margin: 1em 0;
    }
    a {
      color: #1a1a1a;
    }
    a:visited {
      color: #1a1a1a;
    }
    img {
      max-width: 100%;
    }
    svg {
      height: auto;
      max-width: 100%;
    }
    h1, h2, h3, h4, h5, h6 {
      margin-top: 1.4em;
    }
    h5, h6 {
      font-size: 1em;
      font-style: italic;
    }
    h6 {
      font-weight: normal;
    }
    ol, ul {
      padding-left: 1.7em;
      margin-top: 1em;
    }
    li > ol, li > ul {
      margin-top: 0;
    }
    blockquote {
      margin: 1em 0 1em 1.7em;
      padding-left: 1em;
      border-left: 2px solid #e6e6e6;
      color: #606060;
    }
    code {
      font-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;
      font-size: 85%;
      margin: 0;
      hyphens: manual;
    }
    pre {
      margin: 1em 0;
      overflow: auto;
    }
    pre code {
      padding: 0;
      overflow: visible;
      overflow-wrap: normal;
    }
    .sourceCode {
     background-color: transparent;
     overflow: visible;
    }
    hr {
      background-color: #1a1a1a;
      border: none;
      height: 1px;
      margin: 1em 0;
    }
    table {
      margin: 1em 0;
      border-collapse: collapse;
      width: 100%;
      overflow-x: auto;
      display: block;
      font-variant-numeric: lining-nums tabular-nums;
    }
    table caption {
      margin-bottom: 0.75em;
    }
    tbody {
      margin-top: 0.5em;
      border-top: 1px solid #1a1a1a;
      border-bottom: 1px solid #1a1a1a;
    }
    th {
      border-top: 1px solid #1a1a1a;
      padding: 0.25em 0.5em 0.25em 0.5em;
    }
    td {
      padding: 0.125em 0.5em 0.25em 0.5em;
    }
    header {
      margin-bottom: 4em;
      text-align: center;
    }
    #TOC li {
      list-style: none;
    }
    #TOC ul {
      padding-left: 1.3em;
    }
    #TOC > ul {
      padding-left: 0;
    }
    #TOC a:not(:hover) {
      text-decoration: none;
    }
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
  </style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">2804癌症传EN081-2026年01月27日-癌症传EN</h1>
<p class="author">hbaolong@vip.qq.com</p>
</header>
<center>
<a href="/3place/azzen">返回首页</a> <a
href="/3place/azzen/mingju.html">本书名句</a> <a
href="/3place/azzen/memo.html">本书注解</a> <a
href="/3place/azzen/index_rich.html">丰富目录</a> <a
href="/3place/azzen/index_readcal.html">同读日历</a> <a
href="/3place/azzen/index_timeline.html">时间线</a> <a
href="/3place/azzen/index_books.html">引用书籍</a> <a
href="/3place/azzen/index_words.html">使用字频</a>
</center>
<h4 id="curiouser-and-curiouser">“Curiouser and curiouser”</h4>
<p>276 You’re under a lot of stress: Transcript of interview with Barry
Marshall and an anonymous interviewer, National Health and Medical
Research Council archives, Australia.</p>
<p>276 In the early 1970s, for instance, a series of studies: J. S.
Harrington, “Asbestos and Mesothelioma in Man,” Nature 232, no. 5305
(1971): 54–55; P. Enterline, P. DeCoufle, and V. Henderson, “Mortality
in Relation to Occupational Exposure in the Asbestos Industry,” Journal
of Occupational Medicine 14, no. 12 (1972): 897–903; “Asbestos, the
Saver of Lives, Has a Deadly Side,” New York Times, January 21, 1973;
“New Rules Urged For Asbestos Risk,” New York Times, October 5,
1975.</p>
<p>277 In 1971, yet another such study identified: Arthur L. Herbst,
Howard Ulfelder, and David C. Poskanzer, New England Journal of Medicine
284, no. 15 (1971): 878–81.</p>
<p>277 In the late 1960s, a bacteriologist named Bruce Ames: Bruce N.
Ames et al., “Carcinogens Are Mutagens: A Simple Test System Combining
Liver Homogenates for Activation and Bacteria for Detection,”
Proceedings of the National Academy of Sciences of the United States of
America 70, no. 8 (1973): 2281–85; Bruce N. Ames, “An Improved Bacterial
Test System for the Detection and Classification of Mutagens and
Carcinogens,” Proceedings of the National Academy of Sciences of the
United States of America 70, no. 3 (1973): 82–786.</p>
<p>278 So did X-rays, benzene compounds, and nitrosoguanidine:
“Carcinogens as Frameshift Mutagens: Metabolites and Derivatives of
2-Acetylaminofluorene and Other Aromatic Amine Carcinogens,” Proceedings
of the National Academy of Sciences of the United States of America 69,
no. 11 (1972): 3128–32.</p>
<p>278 Not every known carcinogen scored on the test: For DES, see
Ishikawa et al., “Lack of Mutagenicity of Diethylstilbestrol Metabolite
and Analog, (±)-Indenestrols A and B, in Bacterial Assays,” Mutation
Research/Genetic Toxicology 368, nos. 3–4 (1996): 261–65; for asbestos,
see K. Szyba and A. Lange, “Presentation of Benzo(a)pyrene to Microsomal
Enzymes by Asbestos Fibers in the Salmonella/Mammalian Microsome
Mutagenicity Test,” Environmental Health Perspectives 51 (1983):
337–41.</p>
<p>278 A biochemistry student at Oxford: Marc A. Shampo and Robert A.
Kyle, “Baruch Blumberg—Work on Hepatitis B Virus,” Mayo Clinic
Proceedings 78, no. 9 (2003): 1186.</p>
<p>279 The work of Baruch Blumberg: Baruch S. Blumberg, “Australia
Antigen and the Biology of Hepatitis B,” Science 197, no. 4298 (1977):
17–25; Rolf Zetterstöm, “Nobel Prize to Baruch Blumberg for the
Discovery of the Aetiology of Hepatitis B,” Acta Paediatrica 97, no. 3
(2008): 384–87; Shampo and Kyle, “Baruch Blumberg,” 1186.</p>
<p>279 Blumberg began to scour far-flung places: A. C. Allison et al.,
“Haptoglobin Types in British, Spanish, Basque and Nigerian African
Populations,” Nature 181 (1958): 824–25.</p>
<p>279 In 1964, after a brief tenure at the NIH: Zetterstöm, “Nobel
Prize to Baruch Blumberg.”</p>
<p>279 One blood antigen that intrigued him: Baruch S. Blumberg, Harvey
J. Alter, and Sam Visnich, “A ‘New’ Antigen in Leukemia Sera,” Journal
of the American Medical Association 191, no. 7 (1965): 541–46.</p>
<p>279 In 1966, Blumberg’s lab set out to characterize: Baruch S.
Blumberg et al., “A Serum Antigen (Australia Antigen) in Down’s
Syndrome, Leukemia, and Hepatitis,” Annals of Internal Medicine 66, no.
5 (1967): 924–31.</p>
<p>279 Au and hepatitis: Blumberg, “Australia Antigen and the Biology of
Hepatitis B.”</p>
<p>280 “roughly circular . . . about forty-two nanometers”: Baruch
Blumberg, Hepatitis B: The Hunt for a Killer Virus (Princeton: Princeton
University Press, 2002), 115.</p>
<p>280 By 1969, Japanese researchers: Baruch S. Blumberg, “Australia
Antigen and the Biology of Hepatitis B.”; K. Okochi and S. Murakami,
“Observations on Australia Antigen in Japanese,” Vox Sanguinis 15, no. 5
(1968): 374–85.</p>
<p>280 But another illness soon stood out: Blumberg, Hepatitis B,
155.</p>
<p>281 “discipline-determined rigidity of the constituent institutes”:
Ibid., 72.</p>
<p>281 By 1979, his group had devised one: Ibid., 134–46.</p>
<p>282 “Since the early days of medical bacteriology”: J. Robin Warren,
“Helicobacter: The Ease and Difficulty of a New Discovery (Nobel
Lecture),” ChemMedChem 1, no. 7 (2006): 672–85.</p>
<p>282 Barry Marshall and Robin Warren’s discovery of ulcer-causing
bacteria: J. R. Warren, “Unidentified Curved Bacteria on Gastric
Epithelium in Active Chronic Gastritis,” Lancet 321, no. 8336 (1983):
1273–75; Barry J. Marshall and J. Robin Warren, “Unidentified Curved
Bacilli in the Stomach of Patients with Gastritis and Peptic
Ulceration,” Lancet 323, no. 8390 (1984): 1311–15; Barry Marshall,
Helicobacter Pioneers: Firsthand Accounts from the Scientists Who
Discovered Helicobacters, 1892–1982 (Hoboken, NJ: Wiley-Blackwell,
2002); Warren, “Helicobacter: The Ease and Difficulty”; Barry J.
Marshall, “Heliobacter Connections,” ChemMedChem 1, no. 8 (2006):
783–802.</p>
<p>283 “On the morning of the experiment”: Marshall, “Heliobacter
Connections.”</p>
<p>284 The effect of antibiotic therapy on cancer: Johannes G. Kusters,
Arnoud H. M. van Vliet, and Ernst J. Kuipers, “Pathogenesis of
Helicobacter pylori Infection,” Clinical Microbiology Reviews 19, no. 3
(2006): 449–90.</p>
<h6 id="阅读日期-2026年01月27日-2026年01月27日-共-1-天">阅读日期：
2026年01月27日-2026年01月27日 共： 1 天</h6>
<script src="https://giscus.app/client.js"
        data-repo="hbaolong/hbaolong.github.io"
        data-repo-id="R_kgDOLetDQg"
        data-category="General"
        data-category-id="DIC_kwDOLetDQs4CfLEl"
        data-mapping="url"
        data-strict="0"
        data-reactions-enabled="1"
        data-emit-metadata="1"
        data-input-position="top"
        data-theme="preferred_color_scheme"
        data-lang="zh-CN"
        crossorigin="anonymous"
        async>
</script>
</body>
</html>
